Literature DB >> 12027098

Results of vitrectomy in Terson syndrome.

Tarun Sharma1, Lingam Gopal, Jyotirmay Biswas, Mahesh P Shanmugam, Pramod S Bhende, Rajat Agrawal, Nitin S Shetty, Neera Sanduja.   

Abstract

BACKGROUND: To report visual results of vitrectomy in Terson syndrome
MATERIALS AND METHODS: In 11 patients, 15 eyes underwent vitreous surgery for Terson syndrome. The mean follow up was 18.3 months.
RESULTS: An incomplete posterior vitreous separation was noted in 10 eyes (66.7%). An epiretinal membrane was present in 4 eyes (26.7%), and in 3 eyes, a retinal fold along the arcade was noticed. Significant visual improvement occurred in all eyes; visual acuity of 20/40 or better was achieved in 14 eyes (93.3%). Only 3 eyes developed lens opacity after surgery.
CONCLUSION: Vitrectomy in Terson syndrome provides excellent visual recovery. The complication rate, including the development of cataract, is low.

Entities:  

Mesh:

Year:  2002        PMID: 12027098

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers        ISSN: 1082-3069


  4 in total

1.  25G compared with 20G vitrectomy under Resight non-contact wide-angle lenses for Terson syndrome.

Authors:  Xinbang Mao; Zhipeng You
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

2.  Clinical features and visual prognostic indicators after vitrectomy for Terson syndrome.

Authors:  Xin Liu; Longfei Yang; Wenrui Cai; Linlin Gao; Yaping Li
Journal:  Eye (Lond)       Date:  2019-08-27       Impact factor: 3.775

3.  Ocular ultrasound as an easy applicable tool for detection of Terson's syndrome after aneurysmal subarachnoid hemorrhage.

Authors:  Patrick Czorlich; Till Burkhardt; Volker Knospe; Gisbert Richard; Eik Vettorazzi; Lars Wagenfeld; Manfred Westphal; Jan Regelsberger; Christos Skevas
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

4.  Delayed closure of macular hole secondary to Terson syndrome after vitrectomy: A case report and literature review.

Authors:  Yan Sheng; Wen Sun; Ye Shen
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.